We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit
Read MoreHide Full Article
Emergent BioSolutions Inc. (EBS - Free Report) announced that it has inked an agreement to acquire the FDA-licensed smallpox vaccine’s business of Sanofi (SNY - Free Report) in an all-cash deal of up to $125 million.
ACAM2000 is the only vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. Emergent BioSolutions will also assume responsibility for Sanofi’s existing 10-year Centers for Disease Control and Prevention or CDC contract with a remaining value of up to approximately $160 million for deliveries of ACAM2000 to the Strategic National Stockpile. The CDC contract was originally valued at up to $425 million which will expire and be up for renewal or extension in 2018.
The deal includes a all-cash consideration of $97.5 million upfront and up to $27.5 million in near-term contingent regulatory and manufacturing-related milestones.
Notably shares of Emergent BioSolutions have underperformed the Zacks classified Medical-Biomed/Genetics industry year to date. While the stock is up 5.1%,the industry witnessed a gain of 9% in the same time period.
Emergent BioSolutions will also buy a U.S. based cGMP bulk manufacturing facility and a lease to a cGMP fill/finish facilityalong with their present staff of about 100 employees.
The acquisition of ACAM2000 is a strategic fit for Emergent BioSolutions which will enable the latter to expand its existing smallpox countermeasure offering and will enable Emergent BioSolutions to diversify its portfolio and enable the company to contribute to revenue meaningfully in 2018 and help it in achieving its goal of $1 billion in total revenue by 2020. The company also expects to generate more than 10% of total revenue from international markets from the deal.
This transaction, expected to close in 2017, is subject to customary closing conditions including antitrust regulatory approval.
Enzo Biochem’s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 30 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 69.9% year to date.
Exelixis’ earnings per share estimates increased from 17 cents to 18 cents for 2017 and from 53 cents to 55 cents for 2018, over last 30 days. The company pulled off positive earnings surprises in all the trailing four quarters, with an average beat of 512.11%. The share price of the company has increased 79.3% year to date.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Emergent BioSolutions to Buy Sanofi's Smallpox Vaccine Unit
Emergent BioSolutions Inc. (EBS - Free Report) announced that it has inked an agreement to acquire the FDA-licensed smallpox vaccine’s business of Sanofi (SNY - Free Report) in an all-cash deal of up to $125 million.
ACAM2000 is the only vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection. Emergent BioSolutions will also assume responsibility for Sanofi’s existing 10-year Centers for Disease Control and Prevention or CDC contract with a remaining value of up to approximately $160 million for deliveries of ACAM2000 to the Strategic National Stockpile. The CDC contract was originally valued at up to $425 million which will expire and be up for renewal or extension in 2018.
The deal includes a all-cash consideration of $97.5 million upfront and up to $27.5 million in near-term contingent regulatory and manufacturing-related milestones.
Notably shares of Emergent BioSolutions have underperformed the Zacks classified Medical-Biomed/Genetics industry year to date. While the stock is up 5.1%,the industry witnessed a gain of 9% in the same time period.
Emergent BioSolutions will also buy a U.S. based cGMP bulk manufacturing facility and a lease to a cGMP fill/finish facilityalong with their present staff of about 100 employees.
The acquisition of ACAM2000 is a strategic fit for Emergent BioSolutions which will enable the latter to expand its existing smallpox countermeasure offering and will enable Emergent BioSolutions to diversify its portfolio and enable the company to contribute to revenue meaningfully in 2018 and help it in achieving its goal of $1 billion in total revenue by 2020. The company also expects to generate more than 10% of total revenue from international markets from the deal.
This transaction, expected to close in 2017, is subject to customary closing conditions including antitrust regulatory approval.
Emergent Biosolutions, Inc. Price and Consensus
Emergent Biosolutions, Inc. Price and Consensus | Emergent Biosolutions, Inc. Quote
Zacks Rank & Stocks to Consider
Emergent BioSolutions currently carries a Zacks Rank #4 (Sell).
Some better-ranked health care stocks in the same space are Enzo Biochem, Inc. (ENZ - Free Report) and Exelixis, Inc. (EXEL - Free Report) . Both Enzo Biochem and Exelixis sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Enzo Biochem’s loss per share estimates narrowed from 12 cents to 7 cents for 2017 and from 11 cents to 3 cents for 2018, over the last 30 days. The company delivered positive earnings surprises in all the trailing four quarters, with an average beat of 55.83%. The share price of the company has increased 69.9% year to date.
Exelixis’ earnings per share estimates increased from 17 cents to 18 cents for 2017 and from 53 cents to 55 cents for 2018, over last 30 days. The company pulled off positive earnings surprises in all the trailing four quarters, with an average beat of 512.11%. The share price of the company has increased 79.3% year to date.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7%, and +90.2% respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation. See Them Free>>